Tate Thigpen

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer · 2011 · 600 citations

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Andreas du Bois, Michael Quinn, Tate Thigpen et al. · Annals of Oncology · 2005 · 465 citations

Medicine, Cancer Management, Reproductive Health +9

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group

Tate Thigpen, Hugh M. Shingleton, Howard D. Homesley et al. · Cancer · 1981 · 294 citations

Response Rate 50, Surgical Oncology, Response Rate 17 +16

Small-Cell Carcinoma of the Lung: Combined Chemotherapy and Radiation

Robert B. Livingston, Terence N. Moore, Lance K. Heilbrun et al. · Annals of Internal Medicine · 1978 · 230 citations

Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

Tate Thigpen, Mark F. Brady, Howard D. Homesley et al. · Journal of Clinical Oncology · 2001 · 189 citations